$1.37
-0.01 (-0.72%)
Open$1.36
Previous Close$1.38
Day High$1.39
Day Low$1.31
52W High$3.20
52W Low$1.28
Volume—
Avg Volume83.4K
Market Cap72.42M
P/E Ratio—
EPS$-0.24
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,008.8% upside
Current
$1.37
$1.37
Target
$28.89
$28.89
$16.92
$28.89 avg
$30.86
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.01M | 9.02M | 8.76M |
| Net Income | -596,230 | -528,269 | -565,775 |
| Profit Margin | -6.6% | -5.9% | -6.5% |
| EBITDA | -746,119 | -716,524 | -642,558 |
| Free Cash Flow | -600,890 | -503,274 | -433,552 |
| Rev Growth | +12.0% | +12.6% | +22.9% |
| Debt/Equity | 0.77 | 0.69 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |